<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01669213</url>
  </required_header>
  <id_info>
    <org_study_id>WSAhn_ramosetron_hypotension</org_study_id>
    <nct_id>NCT01669213</nct_id>
  </id_info>
  <brief_title>Effects of Different Kinds, Different Doses of 5-HT3 Receptor Antagonists on Prevention of Hypotension</brief_title>
  <official_title>Effects of Different Kinds, Different Doses of 5-HT3 Receptor Antagonists on Prevention of Hypotension After Spinal Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate effects of different kinds, different dose of 5-HT3
      receptor antagonists on prevention of hypotension after spinal anesthesia
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>prevention of hypotension by calcaulation the gap between baseline mean arterial pressure and lowest mean arterial pressure measured during 30 minutes after spinal anesthesia.</measure>
    <time_frame>up to 30mins after spinal anesthesia</time_frame>
    <description>comparasion of significantly difference in the gap between baseline mean arterial pressure and lowest mean arterial pressure measured during 30 minutes after spinal anesthesia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>prevention of hypotension bycalculation the gap baseline systolic and diastolic blood pressure and lowerst systolic and diastolic blood pressure</measure>
    <time_frame>up to 30mins after spinal anesthesia</time_frame>
    <description>comparasion of significantly difference in the gap between baseline systolic arterial pressure and lowest systolic arterial pressure measured during 30 minutes after spinal anesthesia and the gap between baseline diastolic arterial pressure and lowest diastolic arterial pressure measured during 30 minutes after spinal anesthesia.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>occurrence ratio of shivering, nausea and vomiting, and usage doses of vasopressor (ephedrine or phenylephrine), and atropine</measure>
    <time_frame>up to 30 min after spinal anesthesia</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hypotension</condition>
  <condition>Shivering</condition>
  <condition>Nausea and Vomiting</condition>
  <condition>Vasopressor</condition>
  <arm_group>
    <arm_group_label>ramosetron 0.3 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>preparation of ramosetron 0.3 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ondansetron 8 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>preparation of ondansetron 8mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ondansetron 4 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>preparation of ondansetron 4mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non 5-HT3 receptor antagonist</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>preparation of normal saline 5 ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ramosetron</intervention_name>
    <description>before 5 minutes spinal anesthesia, injection of ramosetron 0.3 mg</description>
    <arm_group_label>ramosetron 0.3 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ondansetron</intervention_name>
    <description>before 5 minutes spinal anesthesia, injection of ondansetron 8 mg</description>
    <arm_group_label>ondansetron 8 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ondansetron</intervention_name>
    <description>before 5 minutes spinal anesthesia, injection of ondansetron 4 mg</description>
    <arm_group_label>ondansetron 4 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>before 5 minutes spinal anesthesia, injection of normal saline 5 ml</description>
    <arm_group_label>non 5-HT3 receptor antagonist</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing spinal anesthesia

        Exclusion Criteria:

          -  hypersensitivity on 5-HT3 receptor antagonists hypertension cardiovascular disease
             intake of selective serotonin reuptake inhibitor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2012</study_first_submitted>
  <study_first_submitted_qc>August 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2012</study_first_posted>
  <last_update_submitted>August 17, 2012</last_update_submitted>
  <last_update_submitted_qc>August 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Wonsik Ahn</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>5-HT3 receptor antagonist</keyword>
  <keyword>hypotension</keyword>
  <keyword>spinal anesthesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Ramosetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

